MetaCap

Dermata Therapeutics (DRMA) vs HCW Biologics (HCWB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Dermata Therapeutics is the larger company by market cap ($2.5 million vs $2.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DRMA-54.51%HCWB-51.98%
+5%-26%-57%
Oct 7, 20261 yearNov 20, 2026
DRMA-50.05%HCWB-53.18%
+3%-27%-56%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DRMA versus HCWB key metrics
MetricDRMAHCWB
Share price$0.5095$0.7491
Market cap$2.51M$2.35M
1-day change-4.23%+1.90%
EPS (TTM)$-3.28$-9.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$54.23K
Revenue growth (YoY)—-97.89%
Net income (latest FY)$-7.56M$-7.96M
Gross margin—20.00%
Operating margin—-24270.74%
Net margin—-14677.14%
52-week high$4.66$23.94
52-week low$0.50$0.70
Distance from 52-week high-89.07%-96.87%
Analyst consensusnonebuy
Avg. price target upside+685.08%+6307.69%
Average volume2.78M379.38K
Shares outstanding4.93M3.14M
Employees935
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Dermata Therapeutics

DRMA stock →

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

About HCW Biologics

HCWB stock →

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees

DRMA vs HCWB FAQ

Which is bigger, Dermata Therapeutics or HCW Biologics?

Dermata Therapeutics (DRMA) is larger, with a market capitalization of $2.51M compared with $2.35M for HCW Biologics (HCWB).

Are Dermata Therapeutics and HCW Biologics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons